Dr. Ariela Noy is an Attending Physician and member of the Lymphoma Service at Memorial Sloan Kettering in New York City. -She has worked in clinical trials for lymphoma focusing on two main areas: HIV related cancer and areas outside of HIV. In HIV related cancer research, her primary focus has been lymphoma, leading the AIDS Malignancy Consortium (AMC) Lymphoma Working Group from 2009-2019, and serving on the NIH lymphoma Steering Committee. Under her leadership this NIH funded effort –executed practice changing clinical trials including those in diffuse large B cell lymphoma, Burkitt lymphoma and autologous and allogeneic transplantation in people living with HIV. These trials used novel agents and worked collaboratively to elucidate the pathogenesis of HIV lymphomas. The AMC also partnered with other research consortia and international investigators. Current investigations include a gene therapy program using a triple anti-sense lentivirus vector to create HIV resistant CD4 cells, a novel approach to plasmablastic lymphoma (including those without HIV), and a chimeric antigen receptor T cell protocol.
Dr. Noy is also the site Principle Investigator at Memorial Sloan Kettering Cancer Center (MSKCC) which encompasses trials in Kaposi’s sarcoma and bone marrow transplant. Work in the AMC influenced the development of the first National Comprehensive Cancer Network guidelines for HIV malignancies in 2018 and the American Cancer Society of Clinical Oncology (ASCO) Clinical Trials Eligibility guidelines in 2017. Dr. Noy has served as mentor on many AMC studies to junior investigators. Outside of HIV and cancer, she led the trial that expanded the FDA label for ibrutinib, a Bruton Tyrosine Kinase inhibitor, in the first dedicated trial for relapsed refractory to include marginal zone lymphoma. She is leading an investigator-initiated study phase III frontline marginal zone lymphoma study and another trial studying a novel metabolic agent for relapsed or refractory Burkitt or double/triple hit lymphoma. Her -work for the American Society of Hematology (ASH) includes ASH Ask a Colleague and for ASCO, the recent editor of the SEP Board review section on lymphoma. Her work in Castleman disease extends over nearly 30 years of clinical experience and she is excited to be part of the CDCN Scientific Advisory Board.